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Abstract
Background: Abolishing the inhibitory signal of intracellular cAMP by phosphodiesterases (PDEs) is a prerequisite for
effector T (Teff) cell function. While PDE4 plays a prominent role, its control of cAMP levels in Teff cells is not exclusive. T cell
activation has been shown to induce PDE8, a PDE isoform with 40- to 100-fold greater affinity for cAMP than PDE4. Thus, we
postulated that PDE8 is an important regulator of Teff cell functions.
Methodology/Principal Findings: We found that Teff cells express PDE8 in vivo. Inhibition of PDE8 by the PDE inhibitor
dipyridamole (DP) activates cAMP signaling and suppresses two major integrins involved in Teff cell adhesion. Accordingly,
DP as well as the novel PDE8-selective inhibitor PF-4957325-00 suppress firm attachment of Teff cells to endothelial cells.
Analysis of downstream signaling shows that DP suppresses proliferation and cytokine expression of Teff cells from Crem
2/2
mice lacking the inducible cAMP early repressor (ICER). Importantly, endothelial cells also express PDE8. DP treatment
decreases vascular adhesion molecule and chemokine expression, while upregulating the tight junction molecule claudin-5.
In vivo, DP reduces CXCL12 gene expression as determined by in situ probing of the mouse microvasculature by cell-
selective laser-capture microdissection.
Conclusion/Significance: Collectively, our data identify PDE8 as a novel target for suppression of Teff cell functions,
including adhesion to endothelial cells.
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Introduction
The cyclic nucleotide phosphodiesterase (PDE)4 acts as a
critical regulator of T cell function through its ability to hydrolyze
intracellular cAMP [1–3]. However, substantial evidence sup-
ports the existence of PDE4-independent mechanisms of cAMP
degradation in T cells [4–7]. In PDE4A
2/2 and D
2/2 mice, for
example, T cell function is normal while in PDE4B
2/2 mice,
there is a more pronounced defect in macrophage function than
in T cell proliferation [7]. Similarly, the PDE4-selective inhibitor
rolipram only weakly suppresses proliferation of polyclonal T cell
populations [8,9] despite its effectiveness in selected T cell clones
[10]. Additional analyses indicate that PDE4 accounts for less
than 50% of total PDE activity in T cells [9]. Subsequently, PDEs
other than PDE4 have been identified in T cells, and the overall
PDE activity in T cells in vitro has now been attributed to PDE1,
2, 3, 4, 7 and 8 [4–6,11]. Whether these different PDE activities
identified in vitro operate in vivo remains an active field of
investigation.
cAMP is a potent regulator of the immune response, mainly
through activation of cAMP-dependent protein kinase A (PKA) and
itsestablishedinhibitoryactiononeffectorT (Teff)cells[1,9,12–14].
Activation of receptors coupled to Gs proteins by extracellular
ligands such as catecholamines, prostaglandins and adenosine
causes accumulation of intracellular cAMP and leads to immuno-
suppression invivoand invitro[14–16].Duetothe detailed functional
characterization of individual PDEs within the 11 member gene
family, it is now accepted that distinct PDE isoforms regulate
specific cell functions [2,17]. These properties afford the opportu-
nity to selectively inhibit PDE isoforms to treat defined pathologic
conditions. Thus, the PDE superfamily emerged as a new target for
the development of specific therapeutic agents [11,18].
Notably, rolipram blocks experimental inflammation in animal
models when applied before or during immunization [8,19]. In
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12011contrast, its therapeutic efficacy is highly variable when treatment
is initiated after the appearance of clinical signs [8,19–21]. In
clinical trials, pharmacological inhibitors of PDE4 developed as
potential therapies for treatment of inflammatory diseases were
less efficacious than preclinical data suggested [18,21,22];
consequently, none has yet been approved for clinical use
[23,24]. Consistent with these observations, recent studies
indicated that the high affinity isoforms PDE7A and PDE8A are
required for full T cell activation [5,6].
These puzzling findings led us to question some of the prevailing
assumptions regarding the mechanism of PDE control of cAMP
signaling in T cells, and prompted us to investigate PDE
expression in activated CD4
+ T cells in vivo and the role of distinct
members of the PDE superfamily in CD4
+ T cell functions. The
ability of T cells to firmly arrest on vascular endothelial cells and
subsequently migrate into the target tissue through the endothe-
lium is a key checkpoint during inflammatory lesion formation.
We recently identified PDE8 as a novel target for inhibition of T
cell chemotaxis [25]. However, unlike motility and chemotaxis in
interstitial spaces, T cell interaction with vascular endothelium
must maintain persistent resistance to detachment by disruptive
shear forces of the blood flow [26,27]. In activated T cells, three
major integrins, LFA-1 (aLb2) and the a4 integrins VLA-4 and
a4b7, control essentially all shear-resistant interactions with
endothelial cells.
Since the cAMP-PKA signaling pathway controls Teff cell
adhesion to vascular ligands and regulates vascular barrier
functions [28–31], we tested here the hypothesis that PDE8 –
through hydrolysis of intracellular cAMP – may be an important
regulator of T cell adhesion and thereby serve as a target for the
inhibition of T cell recruitment to vascular endothelium. We now
show that PDE8A is expressed in activated T cells in vivo.
Mechanistic studies demonstrate that inhibiting PDE8 (i) is critical
in rapid suppression of a4 and aL integrin expression and
inhibition of T cell-endothelial cell interaction in vitro, (ii) decreases
vascular adhesion molecule and chemokine expression and
enhances expression of the tight junction molecule claudin-5 on
endothelial cells in vitro and in vivo, and (iii) plays a significant role
in the inhibition of proliferation and T helper-type 1 (Th1)
cytokine production of CD4
+CD25
2 Teff cells through a cAMP-
dependent but inducible cAMP early repressor (ICER)-indepen-
dent mechanism. These data identify a non-redundant role for
PDE8 in controlling T cell functions and have implications for the
development of anti-inflammatory therapies based on targeting
PDEs and activating cAMP signaling.
Results
Activated CD4+ Teff cells express PDE8A in vivo and in
vitro
We have previously reported on PDE8 expression in unac-
tivated and polyclonally stimulated splenocytes, but to date, no in
vivo observations on PDE8 expression in T cells have been
published [25]. To test this, we transferred CD4
+ TCR transgenic
(Tg) T cells into wildtype non-transgenic mice, activated naı ¨ve or
memory Tg T cells with antigen in vivo [32], isolated Tg T cells
(Fig. 1A) and analyzed their expression of PDE genes (Fig. 1B,
Table S1). As expected, activated Tg T cells predominantly
expressed PDE3 and PDE4 genes in vivo (Fig. 1Bi and ii). Our in
vivo findings (Fig. 1B) are consistent with in vitro findings in isolated
CD4
+CD25
2 Teff cells stimulated with anti-CD3 mAb (Fig. 1Ci)
or T cell blasts derived from splenocytes activated with the
mitogen Concanavalin A (Con A) (Fig. 1Di). In addition, CD4
+ Tg
T cells expressed PDE8A in vivo (Fig. 1Biii), in agreement with
results from gene array analyses (S.Z.B.-S., unpublished data).
Expression of the PDE8A gene, a PDE isoform with a very high
affinity for cAMP (Km<0.04–0.15 mM), in CD4
+ T cells and T
cell blasts activated in vivo and in vitro ranged between 20% and
50% of PDE3B and PDE4B expression levels (Fig. 1B, Ci and Di).
Both anti-CD3 mAb activated CD4
+CD25
2 Teff cells and Con A
activated T cell blasts expressed IFN-c, TNF-a, and IL-2 genes
(Fig. 1Cii and Dii). Overall, PDE and Th1 cytokine profiles
between activated CD4
+ T cells and T cell blasts were comparable
and included the expression of PDE8A.
Targeting PDE8 is required for rapid suppression of Teff
cell adhesion to endothelial cells
In activated T cells, heterodimeric integrin molecules contain-
ing the aLo ra4 chain mediate critical interactions with
endothelial cells [26,27]. Regulation of integrin expression and
function at the surface of lymphocytes and granulocytes by
intracellular cAMP has previously been reported [28,33,34]
Among a wide variety of PDE inhibitors tested against PDE8A,
only dipyridamole (DP) was found to inhibit this enzyme with
reported IC50s in the range of 4–9 mM [1,11,35,36]. By exploring
the selective ability of DP to modulate surface expression of the aL
subunit of LFA-1 and a4 subunit of VLA-4 and a4b7 (Fig. S1) we
attempted to define the role of PDE8 in regulating integrins
involved in T cell extravasation and inflammatory diseases
[26,37,38]. Following a 45-min incubation with 100 mMo r
300 mM DP, the frequency of aL
hi and a4
hi Teff cells was
significantly reduced as compared to the vehicle control or
exposure to 10 mM DP (Fig. 2A and B). In contrast, IBMX, a non-
specific PDE inhibitor which inhibits all known PDE gene families
capable of hydrolyzing cAMP with the exception of PDE8
[1,11,35,36] did not significantly reduce integrin surface expres-
sion (Fig. 2A and B). Following the establishment of dose-response
curves (Fig. 2A and B) and based on others’ and our previous
studies [25,39–42], we chose to use DP at a concentration of
100 mM and IBMX at a concentration of 300 mM in all further
assays. To define the role of PDE isoforms in the regulation of T
cell interaction with endothelium, we next tested PDE inhibitors in
T cell blast-endothelial cell adhesion assays (Fig. 2C and D). DP
rapidly reduced adhesion of T cell blasts to bEnd.3 endothelial
cells by 73% (Fig. 2C and D and Fig. S4) (*p,0.05, **p,0.001;
one-way ANOVA and Bonferroni t-test). In accordance with
results from FACS analysis of integrin surface expression, an
inhibitory effect was observed with DP while IBMX did not
significantly reduce adhesion (Fig. 2C). In addition, the potent
and highly PDE4-selective inhibitor piclamilast (PICL; IC50=
0.001 mM) (Fig. 2C) and the PDE3-selective inhibitor motapizone
(A.G.V. and S.B., unpublished data) also failed to suppress
adhesion in our assays. Our results are in agreement with a
previous report demonstrating no significant effect of rolipram on
the adhesion of activated T cells to immobilized VCAM-1 and
endothelial cells for up to 8 h of exposure [43]. To further probe
the selectivity of PDE8 action in T cell adhesion, we evaluated our
findings with the recently developed PDE8-selective inhibitor PF-
4957325-00 (IC50=0.0007 mM for PDE8A and ,0.0003 mM for
PDE8B; Table 1, Fig. S2). As with DP, the PDE8-selective
inhibitor PF-4957325-00 suppressed T cell blast adhesion to
endothelial cells by 57 and 29% at 1 mM and 0.1 mM, respectively
(Fig. 2C) (*p,0.05, **p,0.001; one-way ANOVA and Bonferroni
t-test). These results on adhesion are notable since in proliferation
studies, PICL was significantly more efficient at suppressing Teff
cell proliferation compared to PF-4957325-00, i.e. 95% vs. 43% at
1 mM, respectively (Fig. S3). Our data suggest a selective effect of
PDE8 inhibition on rapid Teff cell adhesion to endothelial cells.
PDE8 in T Cell Function
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12011Figure 1. PDE8 is expressed in activated CD4
+ T cells in vivo and in vitro. (A–D) Gene expression analysis of PDE and effector cytokine genes
in T cell populations. (A) Naı ¨ve T cells from LN of TCR Tg donor mice (5C.C7/RAG-2
2/2/CD45.1 B10.A) were injected i.p. into normal syngeneic CD45.2
B10.A recipient mice and activated by antigen using miniosmotic pumps. Memory cells were generated in vivo by antigen priming and boost using
miniosmotic pumps as described [32]. The LN and SP were removed 20–22 h or 38–44 h later and single cell suspensions (i) were stained with (ii) PE
Cy7 anti-CD4, (ii) PE anti TCR Vb3, (iii) APC anti-CD45.2 and (iii) FITC anti-CD45.1. The Tg T cells were purified by FACS sorting of the CD4
+/TCR Vb3
+/
CD45.1
+/CD45.2
2-population as demonstrated for a representative sample (i–iii). (B) cDNAs were made from the sorted naı ¨ve and memory T cell
populations and relative gene expression of (i) PDE3B, (ii) PDE4B, and (iii) PDE8A was analyzed by qRT-PCR. (C) CD4
+CD25
2 T cells were isolated and
stimulated by plate-bound anti-CD3 mAb (5 mg/ml) in vitro for 18 h, and (D) splenocytes were activated for 48 h with Con A (3 mg/ml). Relative
expression of PDE and effector cytokine genes was determined by qRT-PCR. Values are presented as mean + SEM of the ratio between target gene
expression and RPL19 expression. Data are representative of two to three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0012011.g001
PDE8 in T Cell Function
PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12011We next assessed whether the DP effect is consistent with
signaling through the cAMP pathway, and thus its action as a PDE
inhibitor. PKA inhibits integrin surface expression and avidity on
leukocytes and spatially controls a4 integrin phosphorylation
required for efficient cell migration [44–46]. In our experiments,
dibutyryl-cAMP (Db-cAMP), an agonistic cAMP analog, reduced
T cell blast adhesion to endothelial cells by 81% (Fig. 2D),
comparable to the 73% reduction resulting from DP treatment
(*p,0.05, **p,0.001; one-way ANOVA and Bonferroni t-test).
Besides inhibiting PDE activity, DP blocks the reuptake of
extracellular adenosine which can also increase cAMP synthesis in
T cells. To determine if this mechanism accounts for some of the
Figure 2. Inhibiting PDE8 suppresses integrin surface expression and adhesion of Teff cells to endothelial cells. (A and B) Modulation
of aL and a4 integrin surface expression on Teff cells in response to PDE inhibitors. In both panels, CD4
+CD25
2 Teff cells were treated with DP or
IBMX before analysis of CD4, aL, and a4 integrin cell surface expression by FACS. Cells were gated on the CD4
+ population. Frequency of aL
hi (A) and
a4
hi (B) Teff cells in response to different doses of PDE inhibitors normalized to the vehicle condition set at 100 percent. DP significantly reduced
integrin surface expression while IBMX did not. (C and D) Inhibition of T cell blast adhesion to endothelial cells by DP and PF-4957325-00 within
90 min. T cell blasts from C57BL/6 mice and bEnd.3 endothelial cells were incubated with (C) IBMX (300 mM), PICL (1 or 0.1 mM), DP (100 mM) or PF-
4957325-00 (1 or 0.1 mM), (D) dibutyryl-cAMP (Db-cAMP; 500 mM) or DP in the presence or absence of AD (1 U/ml) or vehicle (0.1% DMSO). Values are
normalized to the vehicle condition and presented as the mean + SEM percentage of T cell blasts resistant to detachment. Data are representative of
one to five independent experiments performed in triplicate (*p,0.05, **p,0.001; one-way ANOVA and Bonferroni t-test).
doi:10.1371/journal.pone.0012011.g002
Table 1. In vitro potency of the PDE8-selective inhibitor PF-
4957325-00.
PDE IC50
8A 0.0007 mM
8B ,0.0003 mM
All other PDE isoforms .1.5 mM
doi:10.1371/journal.pone.0012011.t001
PDE8 in T Cell Function
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(1 U/ml) which has been shown to degrade extracellular
adenosine at this concentration, in the adhesion assay. AD did
not reverse the inhibitory effect of DP on T cell blast adhesion.
Treatment with DP in the presence of AD reduced adhesion by
84% (*p,0.05, **p,0.001; one-way ANOVA and Bonferroni t-
test), similar in magnitude to inhibition obtained with DP alone
(Fig. 2D). These results indicate that DP is not acting through an
effect on extracellular adenosine and support our conclusion that
DP acts as a PDE inhibitor in our experiments.
The recruitment chemokine CXCL12 has been widely shown to
promote adhesion strengthening between T cell integrins and their
vascular ligands after CXCL12 immobilization on the luminal
surface of endothelial cells [26,27]. To test whether CXCL12
could overcome the inhibitory effect of DP on T cell blast-
endothelial cell adhesion, we preincubated activated bEnd.3 cells
with CXCL12 (250 ng/ml) and DP (100 mM) for 45 min before
performing the adhesion assay. Our results show that CXCL12
did not reverse the inhibitory effect of cAMP signaling activated by
DP (Fig. S4).
DP treatment causes a short increase of intracellular
cAMP followed by a compensatory increase of PDE4B
gene expression and suppression of Th1 cytokines in Teff
cells
PDEs are dynamic regulators and rapidly respond to changes
in cAMP levels [1,2]. We found that PDE4B expression was
selectively increased after DP and IBMX treatment, whereas
PDE3B, 7A, and 8A expression were unchanged. Initially
unchanged at 20 min (Fig. 3A), PDE4B gene expression increased
8-fold in CD4
+CD25
2 Teff cells after 90 min of DP treatment and
5-fold after IBMX treatment (Fig. 3Bi) (*p,0.05, **p,0.001; one-
way ANOVA and Bonferroni t-test). Of note, we observed an
increase of cAMP at 20 min of DP treatment which was resolved
by 90 min (Fig. 3C). Theses data are the first demonstration of a
compensatory upregulation of PDE4B gene expression in response
to DP action in Teff cells. Despite the increase in PDE4B gene
expression, DP decreased gene expression of TNF-a by 3-fold and
IL-2 by 2-fold in Teff cells after 90 min of exposure. Similar results
were obtained with IBMX (Fig. 3Bii) (*p,0.05, **p,0.001; one-
way ANOVA and Bonferroni t-test). Thus, DP action on Teff cells
causes an increase in cAMP levels after 20 min, and subsequently
a change in expression of PDE4 and Th1 cytokine genes after
90 min (Fig. 3C).
DP suppresses proliferation of Teff cells in the absence of
ICER
Since PDE4-selective inhibitors show limited effects on T cell
proliferation [9] we next tested DP in proliferation assays of
CD4
+CD25
2 Teff cells. In our assays, both IBMX and DP
potently suppressed Teff cell proliferation, but the inhibitory
action of DP was greater (Fig. 4) (*p,0.05, **p,0.001; one-way
ANOVA and Bonferroni t-test). Multiple mechanisms have been
suggested for the suppression of T cell function by cAMP,
including induction of the transcription factor ICER [47]. ICER is
transcribed from an alternative cAMP-inducible promoter of the
Crem gene. Based on the results of our experiments, we directly
addressed the role of ICER in DP and IBMX mediated Teff cell
Figure 3. DP treatment inhibits TNF-a and IL-2 gene expression
and causes a compensatory increase in PDE4B expression. (A
and B) The expression profile of PDE and cytokine genes in Teff cells
following treatment with PDE inhibitors. Purified CD4
+CD25
2 T Teff
cells were incubated with IBMX (300 mM), DP (100 mM) or vehicle (0.1%
DMSO) for (A) 20 or (B) 90 min. PDE (A, Bi) and cytokine (Bii) relative
gene expression was analyzed by qRT-PCR. Values are presented as
mean + SEM of the ratio between target gene expression and RPL19
expression. Data are representative of two independent experiments
performed in triplicate (*p,0.05, **p,0.001; one-way ANOVA and
Bonferroni t-test). (C) Summary of the kinetics of intracellular cAMP
levels, PDE and cytokine gene expression after exposure of Teff cells to
DP (100 mM). Values are presented as relative fold-change compared to
vehicle control at 0 min (set as 1) and data are representative of one to
three independent experiments.
doi:10.1371/journal.pone.0012011.g003
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2/2 mice which lack ICER [48]. We
found that gene deletion of Crem in Teff cells (Crem
2/2/ICER-
deficient Teff cells) did not affect DP mediated suppression of
proliferation (Fig. 4) or Th1 cytokine gene expression (A.G.V. and
S.B., unpublished data). The viability of Teff cells was not affected
by the DP treatment (A.G.V. and S.B., unpublished data). Taken
together, our results suggest a role for PDE8 in controlling Teff cell
proliferation and indicate that the transcriptional repressor ICER
is not required for cAMP mediated suppression.
Endothelial cells express PDE8A
To more fully elucidate the role of PDE8 in rapid cAMP
signaling during T cell–endothelial cell interaction, we extended
our investigations to analyze PDE expression in endothelial cells.
We confirmed expression of PDE1, 2, 3, 4, 5 and 7 genes in
bEnd.3 cells [49,50]. Importantly, we discovered considerable
expression of PDE8A in these cells (Fig. 5A). Similar to Teff cells,
PDE4B was the most abundantly expressed PDE gene in bEnd.3
cells. In contrast, PDE8A expression was 4-fold lower (Fig. 5A).
Nevertheless, the expression level of PDE8 was comparable to that
of PDE2A which was shown to be functionally important in
vascular beds despite its lower abundance [30]. As in Teff cells
(Fig. 3B), activation of cAMP signaling through DP treatment
in bEnd.3 cells induced a compensatory increase of PDE4B
expression while expression of other PDE genes, including
PDE8A, was not significantly altered (Fig. 5A) (*p,0.05,
**p,0.001; unpaired t-test).
DP rapidly increases cAMP levels in endothelial cells
Raising cAMP levels through PDE inhibition in endothelial cells
has been shown to increase barrier function and down regulate
expression of adhesion molecules [29–31]. Here, we tested the
ability of DP and IBMX to increase cAMP levels in bEnd.3 cells.
DP, but not IBMX, increased cAMP levels by over 2-fold within
20 min (Fig. 5B). At 45 min cAMP levels were significantly
increased by both DP and IBMX (Fig. 5B) (*p,0.05, **p,0.001;
one-way ANOVA and Bonferroni t-test). Hence, cAMP is
increased more rapidly by DP than IBMX.
DP suppresses gene expression of vascular T cell
recruitment molecules and induces the tight junction
molecule claudin-5
To further explore the response of endothelial cells to DP, we
tested whether a DP-mediated increase in cAMP caused changes
in gene expression of molecules involved in vascular recruitment of
T cells and the formation of endothelial tight junctions. DP
reduced gene expression of VCAM-1 (Fig. 5Ci), a vascular
adhesion molecule promoting integrin-dependent adhesive inter-
actions of T cells with venules, by 60%. The reduction of VCAM-
1 expression by DP is consistent with the action of two cell
permeable analogs of cAMP, dibutyryl-cAMP and 8-bromo-
cAMP which suppressed VCAM-1 expression by 33% and 55%,
respectively (Fig. 5Ci). DP also reduced gene expression of the
vascular adhesion molecule ICAM-1 by 65%, again consistent
with cAMP-dependent effects as dibutyryl-cAMP inhibited ICAM-
1 by 42% (Fig. 5Cii). Since CXCL12 is a strong recruitment
chemokine for T cells [27], we investigated the effect of DP on its
expression in endothelial cells. DP reduced CXCL12 by 69%
while dibutyryl-cAMP and 8-bromo-cAMP reduced CXCL12 by
48% and 80%, respectively (Fig. 5Ciii). In addition to its
suppression of vascular adhesion molecules and chemokines, the
anti-inflammatory action of cAMP is associated with an increase in
endothelial barrier integrity [29–31]. Therefore, we examined
whether DP caused upregulation of claudin-5 expression, a critical
component of endothelial tight junctions whose activity is required
for endothelial barrier function [51]. Our results show that DP
increased claudin-5 gene expression by 111%, while dibutyryl-
cAMP and 8-bromo-cAMP increased claudin-5 expression by
70% and 67%, respectively (Fig. 5Civ). Thus, inhibition of PDEs
by DP suppressed expression of molecules promoting adhesive
interactions between leukocytes and vascular endothelium while
increasing the expression of claudin-5, an adhesion molecule
critical to the formation of tight endothelial junctions (*p,0.05,
**p,0.001; unpaired t-test).
DP treatment reduces endothelial cell CXCL12 gene
expression at the microvasculature in vivo
CXCL12 is an efficient vascular recruitment chemokine.
Following our in vitro demonstration that CXCL12 mRNA in
endothelial cells was reduced by short term exposure to DP, we
tested the effect of DP on microvascular endothelium in vivo by use
of laser-capture microdissection (LCM). To facilitate selective
capture of endothelial cells by LCM, we employed a staining
procedure that enabled us to spatially resolve endothelial cells, i.e.
CD31
+ cells, from the perivascular border of the glia limitans, i.e.
GFAP
+ astrocytic end feet [52]. To ensure our dissected samples
were highly enriched with microvascular endothelial cells, we
initially evaluated LCM cDNA by analyzing the ratio of CD31/
GFAP copies. A representative analysis is shown (Fig. 6A and B)
for microvessel-derived (CD31
+) and for astrocytic captures, with
the microvessel cDNA containing 2.5-times as many CD31
transcripts as GFAP gene copies. Conversely, astrocyte-selective
(GFAP
+) captures expressed 317-times as many GFAP transcripts
as CD31 gene copies. Furthermore, astrocytes contained no
detectable CXCL12 mRNA, while microvessels readily expressed
CXCL12 (Fig. 6B). The lack of significant CXCL12 transcripts in
resting astrocytes is further evidence that the CXCL12 mRNA was
derived from dissected microvessels. Using this approach, we were
Figure 4. DP inhibits proliferation of Crem
2/2/ICER-deficient
Teff cells. Proliferation of purified Crem
+/+ or Crem
2/2 derived
CD4
+CD25
2 Teff cells exposed to PDE inhibitors. Teff cells (5610
4/well)
were cocultured with irradiated T cell-depleted splenocytes presenting
soluble anti-CD3 mAb or control in the presence of IBMX (300 mM), DP
(100 mM), or vehicle control. The extent of proliferation was determined
by [
3H]thymidine incorporation at 64 h and results are presented as
mean + SEM counts per min (cpm). Data are representative of two
independent experiments performed in triplicate (*p,0.05, **p,0.001;
comparisons to vehicle were analyzed using a one-way ANOVA and
Bonferroni t-test; comparisons between DP and IBMX were performed
using an unpaired t-test).
doi:10.1371/journal.pone.0012011.g004
PDE8 in T Cell Function
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vascular endothelial cells of the blood-brain barrier in vivo. Our
results show that DP treatment reduced CXCL12 gene expression
(73%) in mouse brain microvessels (Fig. 6C) (*p,0.05, **p,0.001;
unpaired t-test).
Discussion
Our results indicate a non-redundant role for PDE8 during
regulation of T cell adhesion to vascular endothelium through the
cAMP signaling pathway. Our analysis demonstrates for the first
time that activated CD4
+ T cells express PDE8 in vivo. The data
further suggest that targeting PDE8 through the use of the PDE
inhibitor DP is critical to rapidly control adhesion and directed
migration of activated T cells. Remarkably, despite abundant
expression of PDE3 and PDE4 in T cells, selective inhibition of
these PDE isoforms fails to inhibit rapid T cell adhesion. In
addition to its immediate effects on T cell adhesion, DP suppresses
CD4
+CD25
2 Teff cell proliferation and Th1 cytokine production.
Besides targeting T cells, DP acts on endothelial cells by altering
gene expression of adhesion, chemotactic and tight junction
molecules in vitro and in vivo. This two pronged control of T cell-
endothelial cell interaction by DP indicates that PDE8 may serve
as a novel target to suppress recruitment of activated T cells from
the bloodstream into tissues during an inflammatory response.
cAMP is the prototypical second messenger which impacts on
almost every aspect of cell activity and exerts myriad yet specific
effects on cell functions [53]. The ability to form site- and function-
specific cAMP gradients within the cell critically depends on its
degradation by PDEs which are pivotal regulators of intracellular
cAMP activity. Observations that inhibition of PDE4, the most
abundantly expressed PDE in T cells, blocks T cell activation and
function through elevating cAMP, prompted the development of
PDE4 inhibitors as potential immunosuppressive therapies
[10,11,18,23,24]. However, none has yet been approved for clinical
use [11,18,23,24] and rolipram failed to suppress CNS inflamma-
tion in MS patients as measured by brain MRI [21]. The recent
discovery of novel PDE variants in T cells [4–6] suggested that
individual PDE isoforms may serve to modulate distinct regulatory
pathways [25]. These findings led us to hypothesize that PDE4-
selective inhibitors may have shown limited efficacy because
important PDE isoforms in activated T cells were not targeted.
To identify potential PDE targets in T cells other than PDE4,
we first analyzed expression of PDE isoforms in vivo. Based on
Figure 5. DP rapidly induces cAMP and modulates expression of genes involved in the regulation of vascular recruitment and
barrier functions in endothelial cells. (A) Relative PDE gene expression in activated bEnd.3 endothelial cells incubated with DP (100 mM) or
vehicle (0.1% DMSO) for 45 min. Values are presented as mean + SEM of the ratio between target gene expression and RPL19 expression. Data are
representative of three independent experiments performed in triplicate (*p,0.05, **p,0.001; unpaired t-test). (B) cAMP content of activated bEnd.3
cells incubated with IBMX (300 mM), DP (100 mM), or vehicle (0.1% DMSO) for 20, 45, and 90 min. Values are presented as mean + SEM pmol cAMP per
10
4 cells determined by ELISA. Data are representative of two independent experiments performed in duplicate (*p,0.05, **p,0.001; one way
ANOVA and Bonferroni t-test for comparisons between vehicle and DP or IBMX and unpaired t-test for comparisons between DP and IBMX). (C)
Modulation of (Ci) VCAM-1, (Cii) ICAM-1, (Ciii) CXCL12, and (Civ) claudin-5 gene expression in activated bEnd.3 cells by DP (100 mM), dibutyryl-cAMP
(Db-cAMP; 500 mM), 8-bromo-cAMP (500 mM), or vehicle (0.1% DMSO, or media) for 45 min. Values are shown as mean + SEM relative target gene
expression in treated sample as percentage of vehicle control. Data are representative of three independent experiments performed in triplicate
(*p,0.05, **p,0.001; unpaired t-test).
doi:10.1371/journal.pone.0012011.g005
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S., unpublished data), we determined PDE8 expression by qRT-
PCR in Teff cell populations and CD4
+ T cells activated by
specific antigen in vivo. We found that in vivo-activated naı ¨ve and
memory T cells and in vitro-activated Teff cells express PDE8A at
lower levels than PDE3B and PDE4B. Despite its lower
expression, the high affinity of PDE8A for cAMP and effects of
intracellular compartmentalization could account for its critical
role in regulating T cell functions [13,35,36]. Thus, our findings
that PDE8A expression levels are comparable between T cells
activated by specific antigen in vivo and polyclonally activated T
cells in vitro suggest a role for the PDE8 family in regulating cAMP
signaling in these cells.
We next asked whether PDE8 controls integrin expression on
CD4
+CD25
2 Teff cells and thus may play a non-redundant role in
T cell adhesion to vasculature – both functions which are known
to be regulated by cAMP [29]. Among molecular pathways that
regulate T cell extravasation, cAMP is of particular interest as it is
Figure 6. Treatment with DP in vivo inhibits gene expression of CXCL12 in microvascular endothelial cells. (A) Isolation of endothelial
cells and astrocytes in situ by laser-capture microdissection. An immunostained cerebellar cryosection from which CD31 positive microvascular
endothelial cells (anti-CD31 mAb/peroxidase-DAB) and GFAP positive astrocytes (anti-GFAP mAb/Alexa Fluor 594) were selectively captured is shown.
(B) CXCL12 gene expression in endothelial cells from mice treated in vivo with DP. After selected tissue areas were captured, gene expression of CD31,
GFAP, and CXCL12 in CD31 positive endothelial cell captures (top panel) and in GFAP positive astrocytic captures (bottom panel) was analyzed by
qRT-PCR. (C) The effect of in vivo treatment with DP on gene expression of CXCL12 in endothelial cells. C57BL/6 mice were given two i.p. injections of
DP (1 mg) or vehicle (0.1% DMSO). CXCL12 gene expression in CD31 positive endothelial cell captures from cerebellar cryosections 30 min after the
last DP treatment is shown. Values are presented as mean + SEM relative CXCL12 gene expression in cell captures from DP treated mice as
percentage of the vehicle control treatment group. Data represent 9000 individual cell-selective captures from at least 20 immunostained cerebellar
cryosections prepared from 2 animals per treatment group (*p,0.05, **p,0.001; unpaired t-test). Microphotographs were taken on an Olympus IX51
inverted microscope at an original magnification of 200x.
doi:10.1371/journal.pone.0012011.g006
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leukocyte chemotaxis as well as endothelial barrier function in
blood and lymphatic vessels [29–31,54]. Previously, we found that
the broad, non-selective PDE inhibitor IBMX produced little
inhibition of directed migration of activated T cells towards the
chemokine CXCL12 [25]. Only the PDE inhibitor DP [35,36,55]
strongly inhibited migration of activated T cells. The spectrum of
PDEs targeted by DP includes PDEs 4-8, 10 and 11 [1,11,56], thus
including the critical PDE8 isoforms. It is important to note that T
cell motility and firm attachment to vascular ligands are
differentially regulated. Unlike migration within tissue parenchy-
ma [26], T cell attachment to endothelial cells is exposed to
disruptive shear forces and is essentially controlled by the function
of LFA-1 (aLb2) and the a4 integrins VLA-4 and a4b7. We found
that expression of integrins controlling shear-resistant vascular
attachment of T cell blasts is significantly reduced by DP
treatment compared to IBMX treatment (Fig. 2A and B).
With regard to integrin functions, recent studies demonstrated
that adhesion of T cells can be blocked by extended treatment (8–
48 h) with the PDE4-selective inhibitor rolipram [43]. To our
surprise, we failed to detect any suppressive effect of the highly
potent PDE4-selective inhibitor PICL on T cell adhesion to
activated endothelial cells within 90 min. In contrast, DP reduced
adhesion of T cell blasts by 73% while PF-4957325-00 reduced
adhesion by a maximum of 53% (Fig. 2C and D). A possible
explanation for the differences in these observations is that PDE4-
selective inhibitors require long term exposure of T cells to achieve
an inhibitory effect on T cell adhesion since exposure of T cells to
rolipram for a period of less than 8 h had no effect on their
adhesion to vascular ligands or endothelial cells [43]. Thus, results
from previous studies are consistent with our observations. Even
under the conditions of long-term exposure, it is notable that DP
inhibited proliferation of CD4
+CD25
2 Teff cells more potently
than IBMX, and that these immunosuppressive effects were
independent of the cAMP induced transcriptional repressor ICER
(Fig. 4). However, PICL was also very efficient at suppressing
proliferation (Fig. S3), while PF-4957325-00 was less potent than
PICL in this assay. Thus, our data suggest that a rapid effect on T
cell adhesion critically depends on a PDE inhibitor that blocks
PDE8 enzymatic activity, while inhibition of Teff cell proliferation
is less dependent on blocking the PDE8 isoform. At present, it is
unknown what accounts for the different short-term versus long-
term effects of selected PDE isoform inhibition during adhesion
and proliferation. A possible mechanism may be that DP and PF-
4957325-00 upregulate intracellular cAMP levels more rapidly
and efficiently than PDE-selective inhibitors that do not block
PDE8, requiring a longer time of action for less efficient PDE
inhibitors during Teff cell adhesion [57]. Since PDE8A is a very
high affinity cAMP-specific PDE with a Km value ranging from
0.04–0.15 mM, 40–100 times lower than that of PDE4, it is likely
to be functioning at lower cAMP concentrations than PDE4 and
may thus be involved in the control of intracellular cAMP
concentrations at basal levels and in the immediate response to
acute increases of cAMP in specific cell regions [35,36,58]. This
mechanism would be consistent with our data.
DP has other actions in addition to its inhibition of selected
PDEs [42], including suppression of adenosine uptake into cells
[59], thereby potentially increasing extracellular adenosine
available in culture medium. To exclude the action of extracellular
adenosine in our assay systems, we tested the effect of DP in the
presence of AD which inactivates adenosine. Both in chemotaxis
[25] and adhesion assays (Fig. 2D), extracellular adenosine was not
responsible for the inhibitory effect of DP, suggesting DP is indeed
acting through PDE inhibition.
In endothelial cells, PDEs are critical in regulating barrier
permeability [29–31]. In agreement with previous reports [49,50],
we find expression of PDE2, PDE3, and abundant expression of
PDE4 in bEnd.3 cells. In addition, we report for the first time
PDE8A expression in mouse endothelial cells. We demonstrate
that inhibiting PDEs with DP decreased gene expression of
VCAM-1 and ICAM-1, as well as CXCL12 in endothelial cells. In
striking contrast to the downregulation of vascular adhesion
molecules VCAM-1 and ICAM-1 that mediate T cell integrin
interactions, DP increased gene expression of claudin-5 (Fig. 5C),
an intercellular adhesion molecule that is a marker for endothelial
tight junctions [51,60]. Its function is non-redundant as claudin-5
is the major claudin identified in normal endothelial cells. Of note,
claudin-5
2/2 mice have a defective blood-brain barrier [60]. We
demonstrate here that DP upregulates cAMP in endothelial cells,
and that cAMP analogs mimic DP effects on endothelial gene
expression. Taken together, DP exerts a two way control of
endothelial function under inflammatory conditions by inhibiting
expression of T cell recruitment molecules and increasing
expression of the tight junction molecule claudin-5.
As isolated microvessels and endothelial cells undergo significant
changes in culture compared to their features in vivo [61], we tested
the effect of DP on the brain microvasculature in situ using LCM.
Confirming our in vitro observations, administering DP in vivo
significantly reduced CXCL12 gene expression (Fig. 6C). This
result demonstrates the feasibility of cell-selective LCM coupled to
gene expression analysis to measure drug effects on the blood-
brain barrier, and specifically supports the concept that the PDE
inhibitor DP has anti-inflammatory action in this vascular bed
[42]. Together with our data on PDE expression analysis of T cells
in vivo, these results suggest that PDE8 is an important target for
inhibiting the recruitment of activated T cells to vascular
endothelium by regulating cAMP signaling in both cell types.
To date, no PDE8-selective inhibitors had been available, and
thus far, DP has been the most potent agent reported to inhibit it
[35,36]. In addition to testing DP, our study now presents for the
first time the characterization of a novel and previously untested
PDE8-selective inhibitor, PF-4957325-00, in Teff cell adhesion
and proliferation studies. It is noteworthy that blocking the a4
subunit of VLA-4 on Teff cells by antibody provides a highly
efficient way to treat numerous autoimmune diseases in animal
models and in humans, including multiple sclerosis [62–67]. Based
on our study, efforts to develop and test selective inhibitors of
PDE8 such as PF-4957325-00 should be undertaken as a means to
develop novel therapeutic agents for treatment of inflammatory
disorders associated with the vascular recruitment of activated T
cells [68–72].
Materials and Methods
Ethics Statement
All mouse experiments were performed according to IACUC-
approved and -supervised protocols at UCHC and NIH.
Animals
6–12 wk old female C57BL/6 mice were from Jackson
Laboratories, Bar Harbor, ME. Crem
2/2mice were bred as
previously described [48]. 5C.C7/RAG-2
2/2/CD45.1 B10.A
and CD45.2 B10.A mice were from Taconic Farms Inc. (Hudson,
NY) [32].
Cell culture
Con A activated mouse splenocytes as a source of T cell blasts
were prepared and cultured as described [25]. CD4
+CD25
2 Teff
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+CD25
+ Treg cells using a
CD4
+CD25
+ Regulatory T Cell Isolation Kit (Miltenyi Biotec,
Auburn, CA) and activated for 18 h on plate-bound anti-CD3
mAb (5 mg/ml). Cells of the murine brain endothelium-derived
cell line bEnd.3 (ATCC, Manassas, VA) were seeded into 24-well
plates (Costar, Cambridge, MA) in DMEM supplemented with
100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-Gluta-
mine, and 10% fetal bovine serum (all Gibco, Carlsbad, CA). All
bEnd.3 cell assays were performed on confluent monolayers of
cultured cells. Endothelial cell passage numbers did not exceed
25.
Generation and isolation of activated CD4+ T cells in vivo
Naı ¨ve T cells (2610
6) from LN and SP of Tg donor mice
(5C.C7/RAG-2-/-/CD45.1 B10.A) were injected i.p. into normal
syngeneic CD45.2 B10.A recipients. The mice were immunized 7–
10 days later by implantation of 3 day miniosmotic pumps
(Durect, Cupertino, CA) containing 400 mg of antigen (pigeon
cytochrome C [PCC], Sigma-Aldrich, Springfield, MO) in HBSS
[32]. The LN and SP were removed 20–22 or 38–44 h later and
the single cell suspensions were stained with FITC anti-CD45.1,
PE anti-Vb3, APC anti-CD45.2 and PE Cy7 anti-CD4 (BD
Biosciences, San Jose, CA). The Tg T cells were purified by FACS
sorting of the CD4
+/Vb3
+/CD45.1
+/CD45.2
2 population and
the purity of the viable sorted Tg T cells was .90%. Induction
and characterization of memory T cells were performed as
previously described [32]. Briefly, memory cells were generated in
vivo by priming transferred Tg T cells through implantation of 7
day miniosmotic pumps containing 1 mg of antigen (PCC) in
HBSS. The mice were boosted at least 3 months after priming by
implantation of 3 day miniosmotic pumps containing 400 mgo f
antigen (PCC) in HBSS. The LN and SP were removed 20–22 or
38–44 h later and the single cell suspensions stained with FITC
anti-CD45.1, PE anti-Vb3, APC anti-CD45.2 and PE Cy7 anti-
CD4. Memory T cells were identified by memory markers as
described [32]. The Tg T cells were purified by FACS sorting of
the CD4
+/Vb3
+/CD45.1
+/CD45.2
2 population; purity of the
viable sorted Tg T cells was .90%.
a4 and aL integrin cell surface staining
CD4
+CD25
2 Teff cells were treated with reagents as described
in Cell treatment and then stained with the following antibodies:
FITC a-CD4 (GK1.5), Biotin a-CD49d (R1-2) followed by
Streptavidin-APC to detect a4 integrin, and PE a-CD11a (2D7)
to detect aL integrin, or IgG2a,k and IgG2b,k as isotype controls
(all Biolegend, San Diego, CA). FACS analysis was performed on a
FACSCalibur 1 instrument (Becton Dickinson, San Jose, CA). Teff
cells expressing high levels of aLo ra4 integrin on their surface
(aL
hi or a4
hi cells) were defined as the cell population staining with
a mean florescence intensity above 10
2 (gated on activated
lymphocytes).
RNA isolation and cDNA synthesis
Sorted Tg T cells from PCC stimulated or unimmunized mice
were lysed in TRIzol (Invitrogen, Carlsbad, CA), RNA extracted
with the RNeasy kit and genomic DNA removed using the RNase-
Free DNase kit (Qiagen, Valencia, CA). RNA quality was
evaluated by the Agilent 2100 Bioanalyzer. RNA from cells was
isolated using the RNeasy mini kit. RNA from LCM studies was
isolated using TRIzol and 4 mg glycogen (Ambion, Austin, TX) as
a RNA carrier. RNA from cells and LCM captures were treated
with Turbo DNA-free Dnase (Ambion). cDNA was synthesized
using Superscript III reverse transcriptase (Invitrogen).
Quantitative real-time RT-PCR analysis
10 ng cDNA, or 2 ml cDNA for LCM studies, was amplified by
qRT-PCR in a 25 ml reaction using SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA). Primers were designed
using Primer Express software v3.0 and primer efficiency verified
by slope analysis to be 100%62.5%. qRT-PCR was performed
using an ABI 7500 fast system and data analyzed using the D
ct
method (SDS software v3.0). Primer sequences (Invitrogen and
IDT, Coralville, IA) are listed in Table S1. Amplicon sizes were
approximately 100 bp.
Cell treatment
In dose-response assays, Teff cells were exposed to 1–300 mM
DP, 10–500 mM IBMX, and 0.01–3 mM PICL as indicated for
45 min. In assays utilizing endothelial cells, confluent bEnd.3
monolayers were activated with 200 ng/ml TNF-a (Peprotech,
Rocky Hill, NJ) at 37uC for 2 h. For adhesion assays or qRT-PCR
analysis, 100 mM DP in the presence or absence of 1 U/ml
adenosine deaminase, 300 mM IBMX, 500 mM 8-bromo-cAMP
(all Sigma-Aldrich), 500 mM dibutyryl-cAMP (Biomol, Plymouth
Meeting, PA), 250 ng/ml CXCL12 (Peprotech), DMEM media or
0.1% DMSO in DMEM media as vehicle controls, 1 and 0.1 mM
motapizone, PICL, or PF-4957325-00 were added to bEnd.3 cells
for the last 45 min of TNF-a incubation. The PDE8-selective
inhibitor PF-4957325-00 was synthesized by Pfizer Inc, Groton
Laboratories, Groton, CT (Table 1, Fig. S2). PF-04957325-00
inhibits PDE8A with an IC50=0.0007 mM and PDE8B with an
IC50 ,0.0003 mM. The IC50 of PF-04957325 for members of all
other PDE families is .1.5 mM. Additionally, PF-04957325 shows
no activity in an off target selectivity panel screened at single dose
at 10 mM concentrations. The PDE3- and PDE4-selective
inhibitors motapizone and PICL were supplied by Drs. Christof
Zitt and Armin Hatzelmann (Nycomed, Konstanz, Germany). T
cell blasts or Teff cells were treated with the same reagents for 20,
45, or 90 min.
In vivo DP treatment
0.4 ml of DP solution (1 mg DP in PBS/0.1% DMSO) or
vehicle control (PBS/0.1% DMSO) were injected into C57BL/6
mice at 0 and 4 h. Mice were sacrificed by CO2 inhalation 30 min
after the last injection, cerebella removed, snap frozen in liquid
nitrogen and stored at 280uC.
Adhesion assays
Adhesion assays were performed in 24-well plates with a
confluent layer of activated bEnd.3 cells. T cell blasts or Teff cells
were labeled with 5 mM Calcein AM (Molecular Probes, Eugene,
OR) and treated as described above. 7610
5 pretreated T cell
blasts or Teff cells per well were incubated on bEnd.3 cells in
RPMI media. After 30 min at 37uC, non-adherent cells were
removed by washing with D-PBS. For analysis, 7610
5 Calcein
AM labeled T cell blasts or Teff cells were used as positive
controls. Fluorescence was read in a Victor 3v microplate reader
(Perkin Elmer, Waltham, MA) with a fluorescein filter set. The
percentage of labeled cells resistant to detachment was calculated
as total fluorescence of well divided by fluorescence of 7610
5
Calcein AM labeled cells.
Laser-capture microdissection (LCM)
7 mm cryosections of frozen cerebella were fixed in acetone and
rapidly stained according to established protocols [52]. Primary rat
anti-CD31 mAb (Pharmingen, San Diego, CA), in conjunction
with a biotinylated anti-rat IgG secondary Ab, avidin:biotinylated
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Labs, Burlingame, CA), were used for brain vascular endothelial
cell detection and Alexa Fluor 594 conjugated anti-GFAP mAb
(Molecular Probes) for astrocyte detection. Selective capture of
microvascular endothelial cells or astrocytes was performed using a
Pixcell II LCM system (Molecular Devices, Sunnyvale, CA). 500
captures of either CD31
+ or GFAP
+ material were taken from a
single slide. Cell captures from three slides were pooled and
reversely transcribed into cDNA for a total of 1500 captures per
cDNA. Three different cDNAs were separately analyzed from
each animal. Two animals were used per treatment group.
Microphotographs were taken on an Olympus IX51 microscope
integrated into the LCM instrument.
Proliferation assays
T cell-depleted splenocytes (Tds) were obtained by negative
selection with murine anti-CD4 and anti-CD8 microbeads
(Miltenyi Biotec). Isolated CD4
+CD25
2 Teff cells (5610
4/well)
were cultured in 96-well plates (Costar) with irradiated Tds
(5610
4/well; 2600 rad) in the presence or absence of soluble anti-
CD3 mAb (0.7 mg/ml) (R&D Systems, Minneapolis, MN). DP
(100 mM), IBMX (300 mM), PICL (1, 0.1 mM), PF-4957325-00 (1,
0.1 mM), or vehicle control (0.1% DMSO in media) were added at
0 h. After 48 h, 2 mCi per well of [
3H]thymidine (NEN, Waltham,
MA) was added and cells were harvested 16 h later using a
semiautomated cell harvester. [
3H]thymidine incorporation was
determined using a b-scintillation counter. Cell viability was
examined in separate T cell cultures using trypan blue (2.5%) at
64 h of incubation.
Intracellular cAMP ELISAs
Activated bEnd.3 cells were treated as described above for 20,
45 or 90 min. cAMP levels were determined with a Correlate
cAMP ELISA kit (Assay Designs, Ann Arbor, MI) using an ELISA
reader (Bio-Rad, Hercules, CA) with the filter set at 405 nm.
Statistics
Experimental groups were compared by analyzing data with the
unpaired t-test or one-way ANOVA followed by Bonferroni t-test
using Sigmastat software (San Jose, CA). Probability levels for
statistically significant differences are indicated by the p-value in
the figure legend and by corresponding asterisks in the figures.
Supporting Information
Table S1 Genes and DNA sequences of forward and reverse
primers used in qRT-PCR.
Found at: doi:10.1371/journal.pone.0012011.s001 (0.07 MB
DOC)
Figure S1 aL and a4 integrin expression on Teff cells. Isotype
control (unfilled histogram) and specific staining (filled histogram)
together with gates for aLhi (Ai) and a4hi (Bi) cells are shown. The
cell population staining with a mean florescence intensity above
102 (gated on activated lymphocytes) was defined as aLhi or a4hi.
Streptavidin-APC was used to detect a4 integrin, and PE a-
CD11a (2D7) to detect aL integrin, or IgG2a,k and IgG2b, k as
isotype controls.
Found at: doi:10.1371/journal.pone.0012011.s002 (0.07 MB TIF)
Figure S2 Figure S2. Structure of the PDE8-selective inhibitor
PF-4957325-00. The PDE8-selective inhibitor PF-4957325-00 was
developed and synthesized by Pfizer Inc.
Found at: doi:10.1371/journal.pone.0012011.s003 (0.13 MB TIF)
Figure S3 Suppression of proliferation is not dependent on
inhibition of PDE8. Proliferation of purified CD4+CD25- Teff
cells in the presence of PDE-selective inhibitors. Teff cells (56104/
well) were cultured on plate-bound anti-CD3 mAb in the presence
of PICL (1 or 0.1 mM), PF-4957325-00 (1 or 0.1 mM), or vehicle
control. The extent of proliferation was determined by [3H]thy-
midine incorporation at 64 h, and results are presented as
percentage of proliferation normalized to the vehicle condition.
Data are the mean + SEM of 1-3 independent experiments
performed in triplicate (*p,0.05, **p,0.001; comparisons to
vehicle were analyzed using a one-way ANOVA and Bonferroni t-
test; comparisons between PICL and PF-4957325-00 were
performed using an unpaired t-test).
Found at: doi:10.1371/journal.pone.0012011.s004 (0.08 MB TIF)
Figure S4 DP mediated suppression of adhesion is not reversed
by CXCL12. Adhesion of T cell blasts to activated bEnd.3 cells in
the presence of CXCL12. Activated T cell blasts were incubated
for 45 min with DP (100 mM) or vehicle (0.1% DMSO).
Separately, activated bEnd.3 endothelial cells were incubated
with DP in the presence or absence of CXCL12 (250 ng/ml) for
45 min before T cell blasts were added to the bEnd.3 cells for the
adhesion assay. Values are presented as the mean + SEM
percentage of T cell blasts resistant to detachment (*p,0.05,
**p,0.001; one-way ANOVA and Bonferroni t-test).
Found at: doi:10.1371/journal.pone.0012011.s005 (0.05 MB TIF)
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